GLP-1 & Incretin Science

Two Answers to the Same Question

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

GLP-1 alone was not enough, and two answers emerged for what to add. Tirzepatide adds GIP receptor agonism within one molecule; CagriSema adds an amylin analogue as a second molecule. REDEFINE 4 tested those strategies against each other for the first time.

Key facts

Tirzepatide's second target
GIP receptor
CagriSema's second target
Amylin receptor
Tirzepatide format
One molecule
CagriSema format
Two molecules combined
First direct test
REDEFINE 4 (NCT06131437)
Retatrutide's answer
Glucagon, as a third receptor

Why a second target was needed

GLP-1 receptor agonism alone reached a ceiling. Semaglutide's 13.7% in SURMOUNT-5 was a real achievement and clearly not the end of what was possible. Every subsequent programme is an answer to the same question, what to add, and the answers diverged sharply.

The GIP answer

Add the other incretin. GIP and GLP-1 are the two hormones behind the incretin effect, and their receptors are structurally related enough that one engineered peptide can engage both. Tirzepatide does this within a single molecule, which is why it has one pharmacokinetic profile rather than two. The mechanism by which GIP contributes remains disputed.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The amylin answer

Add a different satiety pathway entirely. Amylin is co-secreted with insulin and signals satiety through routes distinct from the incretins, including hindbrain structures. Cagrilintide is a long-acting amylin analogue, and CagriSema pairs it with semaglutide as two molecules in one injection, a different pharmacology and a different format at once.

Why REDEFINE 4 could not cleanly separate them

Because the two things vary together. CagriSema differs from tirzepatide in both its second target and its format (amylin versus GIP, and two molecules versus one). A single trial comparing them cannot attribute the difference to either, which is a real limitation of what that comparison could ever establish.

What it did establish

That on this comparison, at these doses, over 84 weeks, CagriSema did not demonstrate non-inferiority to tirzepatide 15 mg: 23.0% against 25.5% on the efficacy estimand. That is one comparison at one dose pair, not a verdict on amylin as a target, and amylin agonists continue in development including within single molecules such as amycretin.

And the third answer

Retatrutide adds glucagon receptor agonism as a third target rather than a second, staying within one molecule. Its direct comparison with tirzepatide, TRIUMPH-5, was scheduled to reach primary completion in November 2026. All three of these are licensed medicines or investigational compounds in registered trials, and none is related to research material.

Quick reference

TargetsMoleculesStatus
SemaglutideGLP-1OneApproved
TirzepatideGLP-1 + GIPOneApproved
CagriSemaGLP-1 + amylinTwoFiled
RetatrutideGLP-1 + GIP + glucagonOneInvestigational

Frequently asked questions

Did REDEFINE 4 show GIP beats amylin?

No. CagriSema differs from tirzepatide in both target and format, so one trial cannot attribute the difference to either.

Is amylin finished as a target?

No. Development continues, including single-molecule GLP-1/amylin agonists such as amycretin.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.